NRG
TEVA icon

Nemes Rush Group’s Teva Pharmaceuticals TEVA Stock Holding History

Nemes Rush Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44K Hold
72
– – ﹤0.01% 764
2026
Q1 		$2.17K Hold
72
– – ﹤0.01% 737
2025
Q4 		$2.25K Buy
+72
New +$1.77K ﹤0.01% 718
2023
Q4 		– Sell
-12
Closed -$123 – 687
2023
Q3 		$123 Buy
+12
New +$112 ﹤0.01% 637

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Nemes Rush Group's TEVA Position: Q2 2026 in Review

Nemes Rush Group held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 72 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Nemes Rush Group first reported a position in TEVA in Q3 2023 and has held it in 4 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Nemes Rush Group held 72 shares of Teva Pharmaceuticals worth $2.44K as of Q2 2026.
  • Nemes Rush Group left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #764 holding.
  • Nemes Rush Group first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.